Redeye updates its estimates and valuation following Momentum Group’s Q2 2026 report.
Ahead of Gofore’s Q2, our estimates are trimmed slightly due to its exit of the product design busin...
Q2: Sales of EUR 45m (36m), adj. EBIT of -EUR 1.1m (-0.
Redeye comments on Alligator Bioscience’s recently announced strategic pivot and accompanying rights...
Incap confirmed its FY2026 net sales growth guidance but downgraded its EBITA guidance.
Redeye updates its estimates and valuation after Lifco’s Q2 2026 report.
Genovis' Q2 came in showing a minor deviation on sales (-5% vs REe) while painting a positive pictur...
Redeye comments on the news of the CEO transition at Elicera and consolidation in Uppsala.
Enviro's second quarter was eventful from a broader news-flow perspective, although the Q2 report it...
Bred tillväxt och stark underliggande resultatutveckling Bruttoresultatet ökade med 17,7 % till 60,...
Stille's Q2 painted a picture of continued sales momentum (+8% vs.
* Another strong quarter for P&M orders * Sales EUR 44.
Vaxxa redovisade ett starkt omsättningslyft i Q2 2026, där nettoomsättningen ökade med 57 % till 29,...
Redeye comments on CLS’s rights issue announcement and updates its valuation of the company accordin...
Redeye retains its positive view of Hansa Biopharma following a transformative second quarter.
Genovis Q2 2026 was characterised by strategic expansion following the KPL acquisition and encouragi...
Stille's Q2 2026 report beat our estimates on sales by ~7%, but showed softer margins than we had pe...
Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.
The prostate theranostics market is expanding fast.
Tonies looks set to report a strong Q2 marked by further accelerating growth, carried by particularl...
